Paradoxical Infertility Induction for Fertility Enhancement

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current fertility treatments, such as in vitro fertilization, are expensive and often ineffective in reversing chronic conditions, leading to emotional and financial burdens on couples struggling with infertility, particularly as women delay childbearing, resulting in a significant number of couples unable to conceive.

Innovation Solution

The method involves inducing temporary infertility in a female subject to trigger a compensatory response, enhancing reproductive capacity by administering pharmacological agents, physical regimens, sleep modulations, or Eastern medicine techniques, allowing the subject to mount a compensatory response without continuous treatment, thereby improving fertility.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional fertility treatments (in vitro fertilization, ovarian stimulation) are administered continuously, then fertility enhancement is attempted, but treatment costs increase significantly and tolerance/rebound symptoms develop

Engineering Contradiction:
Improvefertility enhancement effectivenessVSAvoidfinancial cost and emotional burden
Core Design Contradiction:
ReliabilityVSLoss of energy

Solution Approach 1:

The patent implements periodic administration of infertility-inducing agents followed by interruption periods, rather than continuous treatment. This involves administering the agent for a specific duration to induce infertility, then stopping administration to allow compensatory mechanisms to enhance fertility, creating a cyclical treatment pattern that reduces cumulative costs and avoids tolerance development

Inventive Principle:
Principle #19Periodic action

Solution Approach 2:

The patent inverts the conventional approach by first inducing infertility (the opposite of the desired outcome) to trigger compensatory physiological responses that ultimately enhance fertility. This paradoxical strategy involves administering agents that initially reduce fertility capacity, then allowing the body's compensatory mechanisms to overshoot and improve fertility beyond baseline levels

Inventive Principle:
Principle #13The other way round (Inversion)

2Reliability

If infertility-inducing agents are administered to trigger compensatory response, then reproductive capacity is enhanced, but temporary infertility is induced during treatment

Engineering Contradiction:
Improvereproductive capacity enhancementVSAvoidtime period of induced infertility
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent employs preliminary administration of infertility-inducing agents to trigger compensatory physiological responses before the desired fertility enhancement is needed. By inducing infertility first and allowing compensatory mechanisms to activate during the treatment period, the system prepares the reproductive system for enhanced function after treatment interruption

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent implements dynamic treatment protocols where the duration and dosage of infertility-inducing agents are adjusted based on individual patient responses and compensatory mechanism activation. Treatment periods are optimized to trigger sufficient compensatory responses while minimizing the time of induced infertility, with flexible interruption timing based on physiological feedback

Inventive Principle:
Principle #15Dynamics

Data Source

PatentUS10898128B2Enhancing reproductive capacity by paradoxical therapy
Publication Date: 2021.01.26 PALO ALTO INVESTORS LP

AI summary

Methods of enhancing reproductive capacity in a female subject are provided. Aspects of the methods include inducing infertility in the subject in a manner effective to cause the subject to mount a compensatory response and thereby enhance reproductive capacity in the subject. Systems and kits useful in practicing the methods of the present disclosure are also provided.